Drug Combo May Reduce Risk of Second Stroke
After small or mini-stroke, aspirin plus Plavix tied to lower odds of another event
Source: HealthDay
Related MedlinePlus Pages: Blood Thinners, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 26, 2013 Category: Consumer Health News Source Type: news
International study on fragile newborns challenges current practices
(Children's National Medical Center) One of the largest clinical trials done in infants with congenital heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix) to reduce shunt-related blood flow issues is not effective in the dose studied. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2013 Category: Global & Universal Source Type: news
Plavix No Help in Kids' Cyanotic Heart Disease (CME/CE)
(MedPage Today) -- Children with cyanotic congenital heart disease derived no benefit from prophylactic clopidogrel for shunt thrombosis, a large, randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 20, 2013 Category: Cardiology Source Type: news
Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use - Nishijima DK, Shahlaie K, Sarkar K, Rudisill N, Holmes JF.
The objective was to compare neurological outcomes at 6 months in older patients with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage with those without prior use of these medications. METHODS: This was a r... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - June 17, 2013 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
No Aspirin With Anticoag/Clopidogrel After MI, PCI in AFNo Aspirin With Anticoag/Clopidogrel After MI, PCI in AF
A large national cohort study somewhat confirms what the WOEST trial suggested: that an oral anticoagulant plus one antiplatelet is sufficient in patients with multiple indications for antithrombotic therapy. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Aspirin unneeded with anticoagulation/clopidogrel after MI, PCI in AF
A large national cohort study somewhat confirms what the WOEST trial suggested: that an oral anticoagulant plus one antiplatelet is sufficient in patients with multiple indications for antithrombotic therapy. (Source: theHeart.org)
Source: theHeart.org - June 6, 2013 Category: Cardiology Source Type: news
Concomitant Use of Clopidogrel and Proton-Pump InhibitorConcomitant Use of Clopidogrel and Proton-Pump Inhibitor
PPI's may inhibit more than just proton pumping. Find out the latest on how they compete with clopidogrel. Interventional Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Post-polypectomy Bleeding in Patients on ClopidogrelPost-polypectomy Bleeding in Patients on Clopidogrel
Are patients taking clopidogrel undergoing polypectomy at a greater risk for bleeding after the procedure and, if so, how could it be prevented? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 14, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
French competition body fines Sanofi in Plavix dispute
PARIS (Reuters) - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix. (Source: Reuters: Health)
Source: Reuters: Health - May 14, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Genes a Part of PPI-Clopidogrel Interaction (CME/CE)
ORLANDO (MedPage Today) -- Among patients who have had an MI and who have a genotype associated with ultra-rapid metabolism of clopidogrel, use of proton pump inhibitors may worsen outcomes, a study found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 14, 2013 Category: Cardiology Source Type: news
U.S. spending on medicines fell for first time in 2012
(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - May 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Clopidogrel Boosts Bleeding Risk After PolypectomyClopidogrel Boosts Bleeding Risk After Polypectomy
Patients on clopidogrel have a higher than average risk for bleeding when they have polyps removed during colonoscopy, pooled data suggest. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
STREAM Trial Data Supports An Early Fibrinolysis-Based Strategy For Patients With STEMI Who Cannot Undergo Primary PCI
New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin, followed by timely angiography (pharmaco-invasive strategy), compared to patients given primary PCI after the 60-minute window.(1) "In STEMI patients, the most important thing is to re-establish blood supply to the heart... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
CHMP adopts new indication for new strength of rivaroxaban (Xarelto®)
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a variation to the terms of the marketing authorisation for rivaroxaban (Xarelto®).
The CHMP has adopted a new indication for a new strength 2.5mg as follows: "Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers."
Detailed conditions...
Source: NeLM - Cardiovascular Medicine - March 25, 2013 Category: Cardiology Source Type: news
NEJM Paper Confirms Value Of Early Fibrinolysis In STEMI
New England Journal of Medicine (NEJM) paper shows prehospital or early fibrinolysis with Metalyse® (tenecteplase) delivers comparable clinical outcomes to gold standard intervention for patients who would not have access to primary PCI within 60 minutes after the first medical contact(b) New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
